Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 3:13:58-66.
eCollection 2014.

Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor-α (TNFα) concentration in chronic heart failure

IrajI Khodadadi  1 , Mohammad Saleh Vahedi  2 , Mohammad Abdi  3 , Nasrin Daneshkhah  2 , Rezgar Rahbari  3 , Shahoo Menbari  3 , Dara Ahmadi  4 , Abbas Ahmadi  5 , Fariba Lahoorpour  3 , Mohammad Saied Hakhamaneshi  6 , Saman Javid  1 , Bahram Nikkhoo  3
Affiliations

Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor-α (TNFα) concentration in chronic heart failure

IrajI Khodadadi et al. EXCLI J. .

Abstract

Introduction: Chronic heart failure (CHF) has recently been considered as an inflammatory disease. Enhanced production of tumor necrosis factor-α (TNFα) in CHF patients has been proved. To compensate deleterious effects of TNα, the concentration of adenosine is increased in CHF. However, concurrent determination of serum TNFα and enzymatic activities of ADA and its ADA1 and ADA2 isoenzymes, as the main regulators of adenosine concentration, has not yet been carried out.

Materials and methods: Blood samples were collected from 52 CHF patients and 55 healthy controls. Laboratory routine tests were performed, and after determining the concentration of TNFα, total ADA (tADA) as well as ADA1 and ADA2 isoenzyme activities were measured.

Results: Mean concentration of TNFα increased over 2 fold in CHF patients (12.54 ± 11.69 pg/ml compared with 6.0 ± 6.58 pg/ml in controls). The highest level of TNFα was observed in patients with the final stage of the disease (NHYA IV subgroup), according to the New York Heart Association classification. tADA activity was significantly lower in CHF patients compared with controls (19.29 ± 9.73 and 24.3 ± 6.01 U/L, respectively). ADA2 activity markedly decreased in CHF patients and showed a direct correlation with tADA (r = 0.641, P = 0001). In addition, the lowest levels of tADA and ADA2 activities were observed in patients from the 4(th) quartile of NYHA classification.

Conclusion: Adenosine deaminase activity is reduced in CHF patients to give rise to the concentration of adenosine, thereby attenuating pathologic consequences of CHF. Therefore, it is concluded that ADA activity is of paramount importance in pathophysiology of heart failure and might be used for diagnostic purposes or treatment targets.

Keywords: Adenosine deaminase; heart failure; isoenzymes; tumor necrosis factor-alpha.

PubMed Disclaimer

Figures

Table 1
Table 1. Clinical characteristic of patients and healthy subjects
Table 2
Table 2. Comparison of some serum biological parameters in CHF patients and healthy subjects
Table 3
Table 3. Serum adenosine deaminase and TNFα concentration in patients and healthy subjects
Figure 1
Figure 1. Correlation of serum enzymatic activities of total adenosine deaminase (tADA) with ADA2 isoenzyme in CHF patients
See this image and copyright information in PMC

References

    1. Asakura M, Asanuma H, Kim J, Liao Y, Nakamaru K, Fujita M, et al. Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. Hypertens Res. 2007;30:781–787. - PubMed
    1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823. - PubMed
    1. Deswal A, Petersen N, Feldman A, Young J, White B, Mann D. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST) Circulation. 2001;103:2055–2059. - PubMed
    1. Flores-Arredondo J, Garcia-Rivas G, Torre-Amione G. Immune modulation in heart failure: past challenges and future hopes. Curr Heart Fail Rep. 2011;8:28–37. - PubMed
    1. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation. 1990;82:1724–1729. - PubMed

LinkOut - more resources